 |
 |
It shouldn't take long for this to get back on the US market now! Wilson DeCamp Leesburg, VA UCB Brings Neupro Back to All Patients in Europe From the PharmaLive.com News Archive - Jun. 29, 2009 European Commission lifts the treatment restrictions for NeuproŽ NeuproŽ can be prescribed for all patients in accordance with the approved indications NeuproŽ available again to all patients with Parkinson's disease NeuproŽ newly available to adult patients with moderate to severe Restless Legs Syndrome Brussels (Belgium), 29 June 2009 - press release, regulated information - UCB announced today that NeuproŽ (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe and is newly available for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults. This follows the decision of the European Commission to lift treatment restrictions on NeuproŽ in line with the recommendation of the European Medicines Agency (EMEA), issued on 29 May 2009. "We are delighted that all patients with Parkinson's disease in Europe can once again benefit from continuous drug delivery and the improvement in symptoms that is offered with NeuproŽ and that, for the first time, people with RLS in Europe will also experience the advantages of this important treatment," said Troy Cox, Senior Vice President CNS Operations, UCB. Since June 2008, NeuproŽ supply in Europe has been limited to patients already established on the drug while a new cold-chain storage and distribution system was developed to meet the need for refrigeration of the product from manufacturer to patient. Following full implementation of this system, refrigerated stocks of NeuproŽ are available in all doses so NeuproŽ can be prescribed by European physicians for all patients with idiopathic Parkinson's disease. NeuproŽ in Parkinson's disease Parkinson's disease affects over six million people worldwide and approximately three million patients in the seven major markets (U.S., Japan, Germany, UK, France, Italy and Spain). Formulated as a once-a-day transdermal patch, NeuproŽ continuous drug delivery provides stable drug levels in the bloodstream. NeuproŽ provides statistically significant and clinically relevant improvements in movement and ability to carry out everyday activities in people with early-stage Parkinson's disease and significantly reduces off time and increases on time in people with later stage Parkinson's disease. NeuproŽ is generally well-tolerated. Adverse drug reactions reported in more than 10% of Parkinson's patients treated with NeuproŽ are nausea, dizziness, somnolence and application site reactions. NeuproŽ in RLS In August 2008, the European Commission approved NeuproŽ for the symptomatic treatment of idiopathic moderate to severe RLS in adults. The UK and Germany are the first European countries to launch NeuproŽ (1 mg/24 h, 2 mg/24 h and 3 mg/24 h) in this new indication. RLS affects between 3 and 10% of the population to some extent. In a clinical trial of 458 patients with moderate to severe RLS, NeuproŽ (1 mg/24 h, 2 mg/24 h and 3 mg/24 h dose) proved more efficacious than placebo in relieving bedtime, night and daytime symptoms in patients over a six month treatment period. NeuproŽ was shown to reduce symptoms by >=50% in over half of patients (54.2%) compared to symptom reduction in approximately one third (29.9%) of patients on placebo. In addition more patients receiving NeuproŽ (3 mg/24 h) achieved clinical remission (47.3% vs. 22.8% placebo) and symptom freedom (31.3% vs. 12.3% placebo). "We look forward to having NeuproŽ available as a new treatment option for RLS patients. The results of this rotigotine trial demonstrated efficacy, increased opportunity for symptom freedom in moderate to severely affected RLS patients and improvements to patients' quality of life" said Dr Claudia Trenkwalder from the Paracelsus-Elena Hospital, Kassel, Germany and lead investigator of the study. Further information Antje Witte, Corporate Communications & Investor Relations, UCB T +32.2.559.9414, [log in to unmask] Michael Tuck-Sherman, Investor Relations, UCB T +32.2.559.9712, [log in to unmask] Nancy Nackaerts, External Communications, UCB T +32.2.559.9264, [log in to unmask] Eimear O'Brien, Global CNS Communications Manager, UCB T +32.2.559.9271, [log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn